Laureate Announces Second Manufacturing Agreement with Cytheris



    
    Laureate to Manufacture Cytheris' Lead Product Candidate, INTERLEUKIN-7,
    currently in clinical trials for treatment of HIV, HCV and cancer
    

    PRINCETON, N.J. and PARIS, March 27 /CNW/ -- Laureate Pharma, Inc., a
full-service biopharmaceutical development and protein production company,
announced today that it has entered into a cGMP contract manufacturing
agreement with Cytheris SA, a clinical stage biopharmaceutical company focused
on research and development of new therapies for immune modulation. According
to the agreement, Laureate will manufacture Cytheris' lead product candidate,
Interleukin-7 (IL-7), a fully glycosylated recombinant human protein and
critical growth factor for immune T-cell recovery, for use in ongoing
international clinical trials currently being conducted for treatment of HIV,
HCV and cancer.  Terms and conditions of the agreement were not disclosed.
    
    (Logo:  http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )
    
    Recombinant human Interleukin-7 (r-hIL-7) is a critical growth factor for
immune T-cell recovery and enhancement. Clinical investigations conducted on
more than 75 patients in Europe, the U.S. and Canada have suggested the
potential of r-hIL-7 to expand and protect CD4+ and CD8+ T-cells.
    "We are delighted that Cytheris has selected us again as their CMO, to
manufacture IL-7 in support of their expanded clinical trial program.  This is
a testimonial to our successful partnership with our clients and our effort to
achieve their total satisfaction in our ability to meet their manufacturing
needs," said Robert J. Broeze, Ph.D., President & CEO of Laureate.  "We will
work with the Cytheris team very closely and help them realize the greatest
potential of their IL-7 development and production program."
    "As we move towards large scale production of our IL-7 biotherapeutic, we
are pleased to continue our strong working relationship with Laureate Pharma,"
said Michel Morre, DVM, President and CEO of Cytheris.  "With Laureate's
demonstrated skill in successful transfer of process technology, we look
forward to continuing to work together in the process scale-up, engineering
and clinical material production of IL-7 for our ongoing clinical trials
investigating multiple indications."
    
    About Laureate Pharma, Inc.
    
    Laureate Pharma is a full-service biopharmaceutical development and
protein production company located in Princeton, New Jersey. Laureate Pharma
offers superior bioprocessing services that accelerate new products from
development through production. Laureate provides a wide range of specialized
services from process design and development to full-scale cGMP production,
purification, aseptic filling, testing, validation, analytical services, and
regulatory support. Laureate is focused on two active segments of the
biopharmaceutical industry: monoclonal antibodies and recombinant protein
products. Laureate Pharma, Inc. is a wholly owned subsidiary of Safeguard
Scientifics, Inc. (NYSE:   SFE) (http://www.safeguard.com). For more
information, contact Michael Cavanaugh, Vice President Sales, Marketing, and
Business Development at (609) 919-3400, or info@laureatepharma.com or visit
http://www.laureatepharma.com.
    
    About Cytheris SA
    
    Cytheris SA is a privately held clinical-stage biopharmaceutical company
focused on research and development of new therapies for immune modulation.
These drugs aim at reconstituting and enhancing the immune systems of patients
suffering from cancer, chronic viral or bacterial infections such as HIV and
HCV, or lympho-depleting treatments such as chemotherapy, radiotherapy, bone
marrow transplantation (BMT) and hematopoietic cell transplantation (HCT). The
company operates from its headquarters and laboratories in Issy-les-
Moulineaux, a suburb of Paris, and its U.S. subsidiary in Rockville, Maryland.
For more information, please contact Andrew Lloyd, Andrew Lloyd & Associates:
(allo@ala.com), Gilles Petitot (gilles@ala.com) at +33 1 5654 0700 or visit
http://www.cytheris.com.




For further information:

For further information: Michael Cavanaugh, Vice President Sales, 
Marketing, and Business Development for Laureate Pharma, Inc.,
+1-609-919-3400,  info@laureatepharma.com; or Andrew Lloyd of Andrew Lloyd &
Associates for  Cytheris SA, allo@ala.com; or Gilles Petitot for Cytheris SA, 
+33-1-5654-0700, gilles@ala.com Web Site: http://www.laureatepharma.com      
           http://www.safeguard.com                  http://www.cytheris.com

Organization Profile

LAUREATE PHARMA, INC.

More on this organization

CYTHERIS SA

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890